Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H26O2 |
Molecular Weight | 298.4192 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C(C)[C@]34C
InChI
InChIKey=PEPMWUSGRKINHX-TXTPUJOMSA-N
InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1
Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. It is an aromatase inhibitor. Atamestane lacks other intrinsic hormonal or antihormonal activities and shows no inhibition of other cytochrome-P450 dependent enzymes of adrenal steroidogenesis. It had been in phase III clinical trial for the treatment of breast cancer and phase II for the treatment of benign prostatic hyperplasia. It was discontinued from development after an 865-patient trial in breast cancer showed no improvement in efficacy over letrozole.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3754599
Curator's Comment: https://encrypted.google.com/patents/WO1986005813A1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P11511 Gene ID: 1588.0 Gene Symbol: CYP19A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7682838 |
0.4 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8876703
Curator's Comment: Oral: https://clinicaltrials.gov/ct2/show/NCT00010322
Atamestane is administered over 48 weeks as a daily dose of 100 mg or 300 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10731111
The levels of aromatase mRNA was 6.31 amol/ug total RNA in JEG-3 cells, cultured in the presence or absence of 10 uM Atamestane at 37°C for 24 h.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2017
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12194
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
5824
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
100000086630
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
96301-34-7
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
57050
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
DTXSID30869268
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
C1224
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
C048751
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
Atamestane
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
SUB05588MIG
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105987
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY | |||
|
62GA3K28B6
Created by
admin on Sat Dec 16 16:45:40 GMT 2023 , Edited by admin on Sat Dec 16 16:45:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY